Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | FAAH | O00519 | 5/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.34 |
| ▸ | PLAT | P00750 | 1/20 | 0.33 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | MMP13 | P45452 | 1/20 | 0.33 |
| ▸ | MMP14 | P50281 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4293435 | 0.81 | KMT2A (0.35) | KMT2AFAAHADORA3GAA | |
| SCHEMBL12050045 | 0.75 | CYP1A2 (0.45) | KMT2AFAAHADORA3GAACYP1A2 | |
| SCHEMBL1233462 | 0.74 | CYP1A2 (0.44) | KMT2AFAAHADORA3GAACYP1A2 | |
| SCHEMBL1232307 | 0.73 | KDM4E (0.44) | KMT2AADORA3GAACYP1A2 | |
| SCHEMBL1234127 | 0.72 | AURKA (0.52) | KMT2AFAAHADORA3GAACYP1A2 | |
| SCHEMBL29834790 | 0.72 | CNR2 (0.46) | CYP1A2 | |
| SCHEMBL19616009 | 0.72 | CNR1 (0.42) | KMT2AADORA3GAACYP1A2 | |
| SCHEMBL19615649 | 0.71 | CYP1A2 (0.41) | KMT2AFAAHADORA3GAACYP1A2 | |
| SCHEMBL15964791 | 0.71 | LMNA (0.47) | KMT2AFAAHCYP1A2 | |
| SCHEMBL1198404 | 0.70 | PTGER1 (0.43) | KMT2AADORA3GAACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008139941-A1 | SUBSTITUTED IMIDAZOLE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-11-20 | — | — | WO | disclosed |